| 周永刚,李者龙,邢长洋,杨泽利,金京兰,袁丽君.血浆外泌体microRNA-6886和microRNA-6819在乳腺肿块良恶性鉴别诊断中的价值[J].现代生物医学进展英文版,2021,(20):3898-3902. |
| 血浆外泌体microRNA-6886和microRNA-6819在乳腺肿块良恶性鉴别诊断中的价值 |
| The Value of Plasma Exosomes microRNA-6886 （miR-6886） and MicroRNA-6819 （miR-6819） in Differential Diagnosis of the Benign and Malignant Breast Masses |
| Received:December 27, 2020 Revised:January 23, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.20.019 |
| 中文关键词: 乳腺肿瘤 外泌体 miRNAs 联合诊断 |
| 英文关键词: Breast tumor Plasma exosome MiRNAs Combined diagnosis |
| 基金项目:国家自然科学基金项目(81871357)；陕西省重点研发计划项目（2021SF-007） |
|
| Hits: 1182 |
| Download times: 582 |
| 中文摘要: |
| 摘要 目的：探讨microRNA-6886（miR-6886）和microRNA-6819（miR-6819）在乳腺肿块良恶性患者血浆外泌体中的表达水平及鉴别诊断价值。方法：分别选取41例和18例经病理确诊为乳腺恶性肿块和乳腺良性肿块的患者。通过Exo QuickTM试剂盒分离两组患者血浆外泌体，实时荧光定量PCR检测血浆外泌体中miR-6886、miR-6819和miR-7110的相对表达水平。采用受试者工作特征曲线(ROC)分析单个miRNA或多个miRNA联合在乳腺良恶性肿块鉴别诊断中的价值。各组间比较采用非参数秩和检验进行分析。结果：乳腺恶性肿块组中血浆外泌体miR-6886和miR-6819的表达水平明显低于乳腺良性肿块组，差异具有统计学意义（miR-6886，Z=-2.321，P=0.020；miR-6819，Z=-2.321，P=0.020）。miR-7110的表达水平在两组间没有统计学差异。单个miRNA检测时，miR-6886的AUCROC=0.691，灵敏度和特异度分别为65.8%和72.2%；miR-6819的AUCROC=0.691，灵敏度和特异度分别为73.1%和66.6%；miR-6886和miR-6819联合检测时，AUCROC=0.806，灵敏度和特异度分别为80.5%和77.8%，与单独miR-6886和miR-6819检测相比，AUC差异均有统计学意义（miR-6886，Z=4.082，P＜0.001；miR-6819，Z=2.182，P=0.029）。结论：血浆外泌体miR-6886+miR-6819联合检测，有望成为良好的乳腺良恶性肿瘤鉴别的血清学标志物。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the express levels and diagnostic values of microRNA-6886 （miR-6886） and microRNA-6819 （miR-6819） in plasma exosomes of patients with the benign and malignant breast masses. Methods: The study enrolled 41 patients and 18 ones respectively with pathological diagnosis of breast malignant tumor and benign breast diseases patients. Separating the plasma exosomes of the two-group patients and detecting the relative expression level of the miR-6886, miR-6819 and miR-7110 with real-time fluorescent quantitative PCR. The value of a single miRNA or joint miRNAs in differential diagnosis of the benign and malignant breast masses was analyzed by the receiver-operating characteristic curve (ROC). Groups were compared by nonparametric rank and inspection. Results: The express levels of miR-6886 and miR-6819 of plasma exosomes in the malignant breast tumor group were, significantly lower than those in the benign breast tumor group, which showed statistical difference （miR-6886，Z=-2.321, P=0.020; miR-6819, Z=-2.321, P=0.020）. The expression levels of miR-7110 showed no statistical difference between the two groups. When miR-6886 and miR-6819 was tested separately, the AUCROC of miR-6886 was 0.691, and the sensitivity and specificity were 65.8% and 72.2%; the AUCROC of miR-6819 was 0.691, the sensitivity and specificity were 73.1% and 66.6%. While combining miR-6886and miR-6819, the AUCROC=0.806, the sensitivity and specificity were 80.5% and 77.8%. Comparing with the separated testing, the AUC differences of combining tests were statistically significant (miR-6886, Z=4.082, P<0.001; miR-6819, Z=2.182, P=0.029). Conclusion: The combined detection of plasma exosome, miR-6886 and miR-6819, is expected to be a good serological marker for the differentiation of benign and malignant breast tumors. |
|
View Full Text
View/Add Comment Download reader |
| Close |
